NovoCure Ltd (NAS:NVCR)
$ 23.7 0.95 (4.18%) Market Cap: 2.55 Bil Enterprise Value: 2.17 Bil PE Ratio: 0 PB Ratio: 7.10 GF Score: 60/100

Q3 2019 Novocure Ltd Earnings Call Transcript

Oct 31, 2019 / 12:00PM GMT
Release Date Price: $71.64 (-3.54%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the NovoCure's Third Quarter 2019 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference may be recorded.(Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Ashley Cordova, Senior Vice President of Finance and Investor Relations. Ma'am, you may begin.

Ashley Cordova
NovoCure Limited - VP of Finance & IR

Good morning, everyone, and thank you for joining us to review Novocure's Third quarter 2019 performance. I am joined today by our Executive Chairman, Bill Doyle; our CEO, Asif Danziger; our CFO, Wilco Groenhuysen; our Chief Commercial Officer, Pritesh Shah; and our Chief Medical Officer, Ely Benaim, who will join us for Q&A.

The slides presented today can be viewed on our website, www.novocure.com, by clicking on the link for third quarter 2019 financial results located in the Events section on our Investor Relations page.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot